Cargando…
The efficacy of mesenchymal stem cells in bronchiolitis obliterans syndrome after allogeneic HSCT: A multicenter prospective cohort study
BACKGROUND: Bronchiolitis obliterans syndrome (BOS) after allo-HSCT is a devastating complication with limited therapeutic options. We aimed to assess the efficacy and safety of mesenchymal stem cells (MSCs) in BOS after allo-HSCT. METHODS: This multicenter prospective cohort study enrolled 81 allo-...
Autores principales: | Chen, Shan, Zhao, Ke, Lin, Ren, Wang, Shunqing, Fan, Zhiping, Huang, Fen, Chen, Xiaoyong, Nie, Danian, Du, Xin, Guo, Ziwen, Lin, Dongjun, Xuan, Li, Xu, Na, Sun, Jing, Peng Xiang, Andy, Liu, Qifa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945279/ https://www.ncbi.nlm.nih.gov/pubmed/31668569 http://dx.doi.org/10.1016/j.ebiom.2019.09.039 |
Ejemplares similares
-
Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)
por: Mohseni, Rashin, et al.
Publicado: (2023) -
Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT
por: Xuan, Li, et al.
Publicado: (2016) -
Bronchiolitis obliterans
por: King, Talmadge E.
Publicado: (1989) -
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial
por: Zhao, Ke, et al.
Publicado: (2022) -
Co-transplantation of mesenchymal stem cells makes haploidentical HSCT a potential comparable therapy with matched sibling donor HSCT for patients with severe aplastic anemia
por: Liu, Zenghui, et al.
Publicado: (2020)